TG100-115

製品コードS1352 バッチS135201

印刷

化学情報

Chemical Structure Synonyms N/A Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C18H14N6O2
分子量 346.34 CAS No. 677297-51-7
Solubility (25°C)* 体外 DMSO 9 mg/mL (25.98 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 30%PEG300 65%ddH2O

この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。

 0.400mg/ml (1.15mM) Taking the 1 mL working solution as an example, add 50 μL of 8 mg/ml clarified DMSO stock solution to 300 μL of PEG 300, mix evenly to clarify it; then continue to add 650 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 TG100-115 is a PI3Kγ/δ inhibitor with IC50 of 83 nM/235 nM, with little effect on PI3Kα/β. Phase 1/2.
in vitro TG100-115 inhibits PI3Kγ and -δ, with IC50 of 83 and 235 nM, respectively. This compound is not active for PI3Kα and -β, with IC50 of 1.2 and 1.3 mM. In human umbilical vein endothelial cells (HUVECs), this chemical (up to 10 μM) has no effects on cell proliferation and VEGF-stimulated ERK phosphorylation. However, it (10 μM) interrupts other VEGF signaling pathways, such as those that culminate in VE-cadherin phosphorylation. [1] In HUVECs, this compound (10 μM) inhibits the VEGF-induced increase of total level of VE-cadherin. It inhibits VEGF mediated phosphorylation of mTOR and p70S6 kinase, both of which are downstream of PI3K. This chemical (125 nM to 10 μM) also inhibits FGF-stimulated phosphorylation of Akt. [2]
in vivo In Miles assay models, TG100-115 (1-5 mg/kg) reduces edema formation and inflammation in rats. In rigorous rodent and porcine models of myocardial ischemia (MI), this compound (0.5-5 mg/kg) provides potent cardioprotection, limits infarct development, and preserves myocardial function. [1] In mice, this chemical (5 mg/kg) markedly diminishes vascular permeability (VP) in response to either Sema3A or VEGF, indicating that both factors may depend on PI3Kγ/δ to induce VP. [3] In a mouse asthma model, aerosolized TG100-115 markedly reduces the pulmonary eosinophilia, inhibits interleukin-13 and mucin accumulation. [4]
特徴 A potent and dual selective PI3Kγ/δ inhibitor.

プロトコル(参考用のみ)

キナーゼアッセイ PI3K assays
Forty mL of reaction buffer (20 mM Tris/4 mM MgCl2/10 mM NaCl, pH 7.4) containing 50 mM D-myo-phosphatidylinositol 4,5-bisphosphate substrate and the desired PI3K isoform are aliquoted to 96-well plates; kinase concentrations are 250-500 ng/well, such that linear kinetics are achieved over 90 min. TG100-115 is then added as 2.5 mL of a DMSO stock to final concentration range of 100 mM to 1 nM. Reactions are initiated by addition of 10 mL of ATP to a final concentration of 3 mM, and after 90 min, 50 mL of Kinase-Glo reagent added to quantify residual ATP levels; luminosity is measured using an Ultra 384 instrument. Control reactions omitting either this compound or substrate are also performed. IC50 values are derived from experimental data by nonlinear curve fitting using Prism Version 4.
細胞アッセイ 細胞株 Human umbilical vein endothelial cells (HUVECs)
濃度 10 μM, dissolved in DMSO as stock solution
反応時間 24, 48, and 72 hours
実験の流れ Cells plated in 96-well cluster plates (5 × 103 cells/well) are cultured in assay medium (containing 0.5% serum and 50 ng/ml VEGF) in the presence or absence of TG100-115, and cell numbers are quantified by XTT assay 24, 48, or 72 hours later.
動物実験 動物モデル Rat (Sprague-Dawley) myocardial ischemia (MI) model
投薬量 0.5-5 mg/kg
投与方法 By intravenous injection.

参考

  • https://pubmed.ncbi.nlm.nih.gov/17172449/
  • https://pubmed.ncbi.nlm.nih.gov/17685602/
  • https://pubmed.ncbi.nlm.nih.gov/18180379/
  • https://pubmed.ncbi.nlm.nih.gov/19056934/

カスタマーフィードバック

, , Saraswati Sukumar of Johns Hopkins University School of Medicine

Data from [Data independently produced by , , Biochim Biophys Acta, 2017, 1861(4):947-957]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

PI3Kγ inhibition combined with DNA vaccination unleashes a B-cell-dependent antitumor immunity that hampers pancreatic cancer [ J Exp Clin Cancer Res, 2024, 43(1):157] PubMed: 38824552
Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells [ Function (Oxf), 2023, 4(6):zqad053] PubMed: 37786778
Inactivation of TRPM7 Kinase Targets AKT Signaling and Cyclooxygenase-2 Expression in Human CML Cells [ Function (Oxf), 2023, 4(6):zqad053] PubMed: 37786778
The molecular appearance of native TRPM7 channel complexes identified by high-resolution proteomics [ Elife, 2021, 10e68544] PubMed: 34766907
The FBW7-MCL-1 Axis Is Key in M1 and M2 Macrophage-Related Colon Cancer Cell Progression: Validating the Immunotherapeutic Value of Targeting PI3Kγ [ Exp Mol Med, 2020, 22] PubMed: 32444799
Simultaneous Control of Endogenous and User-Defined Genetic Pathways Using Unique ecDHFR Pharmacological Chaperones. [ Cell Chem Biol, 2020, 24 pii: S2451-9456(20)30080-5] PubMed: 32330442
TRPM7 Kinase Is Essential for Neutrophil Recruitment and Function via Regulation of Akt/mTOR Signaling [ Front Immunol, 2020, 11:606893] PubMed: 33658993
A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues [ J Genet Genomics, 2020, 47(7):389-395] PubMed: 33004309
Suppression of TRPM7 Enhances TRAIL-induced Apoptosis in Triple-Negative Breast Cancer Cells [ J Cell Physiol, 2020, 29] PubMed: 32468675
Inhibition of transient receptor potential melastatin 7 (TRPM7) protects against Schwann cell trans-dedifferentiation and proliferation during Wallerian degeneration [ Anim Cells Syst (Seoul), 2020, 24(4):189-196] PubMed: 33029295

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。